(HealthDay News) – In stable kidney transplant recipients, kidney function, as determined by estimated glomerular filtration rate (eGFR), is independently associated with cardiovascular (CVD) events and death.
Daniel E. Weiner, MD, of Tufts Medical Center in Boston, and colleagues conducted a post hoc analysis of data from 4,016 participants in the Folic Acid for Vascular Outcome Reduction in Transplantation trial to assess CVD and mortality risk factors in renal transplant recipients.
The researchers found that 20% of participants had prior CVD, and the mean eGFR was 49mL/min/1.73m². Over a median of 3.8 years, the researchers identified a total of 527 CVD events in 3,676 participants for whom complete data were available. For those with eGFR values below 45mL/min/1.73m², for every 5mL/min/1.73m² increase in eGFR, the risk of CVD and death was 15% lower (hazard ratio, 0.85 for both), after adjustment. No association was found for those with an eGFR above 45mL/min/1.73m².
“In conclusion, in stable kidney transplant recipients, lower eGFR is independently associated with adverse events, suggesting that reduced kidney function itself rather than preexisting comorbidity may lead to CVD,” the authors write.
PamLab provided the high- and low-dose multivitamins used in the study.